Verve Therapeutics, based in Boston, focuses on gene editing for cardiovascular diseases, employing 255 staff and going public on June 17, 2021. Its lead programs, VERVE-101, VERVE-102, and VERVE-201, target LDL-C-related genes.
VERV filed a patent for "in vivo nickase-based editing of the lpa gene for treatment of cardiovascular disease" on Fri, February 16, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
